{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:27:57Z","timestamp":1793647677850,"version":"4.5.1"},"reference-count":64,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Clonal evolution is a mechanism of treatment resistance against epidermal growth factor receptor inhibitors (EGFRi) in metastatic colorectal cancer (mCRC). When EGFRi is discontinued, EGFRi-resistant tumor subclones decay with time, allowing for EGFRi rechallenge at later time. We conducted a meta-analysis to investigate the efficacy of EGFRi rechallenge in mCRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Clinical trials and observational studies investigating the efficacy of EGFRi rechallenge in mCRC were included from PubMed and Embase from inception to December 8, 2024. Hazard ratios (HRs) of overall survival (OS) and progression-free survival (PFS) were aggregated using Bayesian random-effects models. Objective response rates (ORRs) were aggregated using meta-random-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Twenty-nine studies were included. The pooled median PFS, median OS, and ORR were 3.83 months (95% CI, 3.25 to 4.50), 10.43 months (95% CI, 8.14 to 13.36), and 14.61% (95% CI, 8.70 to 23.51), respectively. EGFRi rechallenge was associated with significantly longer pooled PFS (HR, 0.54 [95% CI, 0.31 to 0.93]) and numerically longer pooled OS (HR, 0.71 [95% CI, 0.46 to 1.09]) than non-EGFRi systemic therapy. Patients without detectable RAS\/RAF mutations by circulating tumor DNA (ctDNA) at the time of EGFRi rechallenge had significantly longer OS (HR, 0.43 [95% CI, 0.24 to 0.75]) and PFS (HR, 0.40 [95% CI, 0.26 to 0.62]) than those with ctDNA RAS\/RAF mutations. Studies with EGFRi-free intervals \u22654 months before rechallenge (18.77%) had a numerically greater pooled ORR than those with EGFRi-free intervals &lt;4 months (6.60%). No unexpected adverse events were reported, and treatment discontinuation because of adverse events was 2.7%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>EGFRi rechallenge is associated with significantly longer PFS, numerically longer OS, and clinically meaningful ORR as compared with non-EGFRi systemic therapy in mCRC, particularly for ctDNA RAS\/RAF wild-type mCRC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-25-00646","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T21:00:04Z","timestamp":1765832404000},"page":"1701-1712","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":3,"title":["Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1200","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2989-9086","authenticated-orcid":true,"given":"Amy H.","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Connecticut School of Medicine, Farmington, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gin Yi","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7479-6803","authenticated-orcid":true,"given":"Chuan Angel","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2758-3077","authenticated-orcid":true,"given":"Ibrahim Halil","family":"Sahin","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7525-8802","authenticated-orcid":true,"given":"Gentry T.","family":"King","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0181-6007","authenticated-orcid":true,"given":"Rachael A.","family":"Safyan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey A.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3375-5912","authenticated-orcid":true,"given":"David B.","family":"Zhen","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8136-6140","authenticated-orcid":true,"given":"Veena","family":"Shankaran","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Harris","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1710-5637","authenticated-orcid":true,"given":"Andrew L.","family":"Coveler","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8586-0234","authenticated-orcid":true,"given":"Jyoti","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1113-7333","authenticated-orcid":true,"given":"Victoria E.","family":"Forbes","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Neag Comprehensive Cancer Center, University of Connecticut School of Medicine, Farmington, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Gold","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Swedish Cancer Institute, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3306-9592","authenticated-orcid":true,"given":"E. Gabriela","family":"Chiorean","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1899-9812","authenticated-orcid":true,"given":"Ronan W.","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Swedish Cancer Institute, Seattle, WA"},{"name":"Department of Medicine, Washington State University College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","unstructured":"FDA approves ERBITUX(R) (cetuximab) as first-line treatment in KRAS mutation-negative (wild-type) epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer in combination with FOLFIRI (irinotecan 5-fluorouracil leucovorin) 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/\/label\/2004\/125084lbl.pdf"},{"key":"e_1_3_7_3_2","unstructured":"Information on cetuximab (marketed as erbitux) 2015"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-577"},{"key":"e_1_3_7_5_2","first-page":"CD007047","article-title":"Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer","volume":"6","author":"Chan DLH","year":"2017","unstructured":"Chan DLH, Segelov E, Wong RS, et al: Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database Syst Rev 6:CD007047, 2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.4428"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu141"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature11156"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01423"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4040"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav4474"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0462"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2821"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy509"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00364"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0715-827b"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"issue":"10","key":"e_1_3_7_18_2","article-title":"Updated guidance for trusted systematic reviews: A new edition of the cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston M","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, et al: Updated guidance for trusted systematic reviews: A new edition of the cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 10(10), 20192019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_3_7_20_2","first-page":"i4919","article-title":"Risk of bias in non-randomized studies of interventions (ROBINS-I): Detailed guidance","volume":"355","author":"J\u00fcni P","year":"2016","unstructured":"J\u00fcni P, Loke Y, Pigott T, et al: Risk of bias in non-randomized studies of interventions (ROBINS-I): Detailed guidance. Br Med J 355:i4919, 2016","journal-title":"Br Med J"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1037\/tra0001316"},{"key":"e_1_3_7_23_2","article-title":"RAS mutations in circulating tumor DNA and clinical outcomes of rechallenge treatment with anti-EGFR antibodies in patients with metastatic colorectal cancer","author":"Sunakawa Y","unstructured":"Sunakawa Y, Nakamura M, Ishizaki M, et al: RAS mutations in circulating tumor DNA and clinical outcomes of rechallenge treatment with anti-EGFR antibodies in patients with metastatic colorectal cancer. JCO Precis Oncol 10.1200\/PO.20.00109","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34632"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0655"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-02868-x"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab012"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00963-9"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34531"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01886-0"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac222"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2915"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00845-y"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01042-w"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5080"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1159\/000346328"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr623"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0452"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1177\/03008916221122554"},{"key":"e_1_3_7_40_2","first-page":"6459","article-title":"Anti-epidermal growth factor receptor antibody readministration in chemorefractory metastatic colorectal cancer","volume":"37","author":"Kajitani T","year":"2017","unstructured":"Kajitani T, Makiyama A, Arita S, et al: Anti-epidermal growth factor receptor antibody readministration in chemorefractory metastatic colorectal cancer. Anticancer Res 37:6459-6468, 2017","journal-title":"Anticancer Res"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01062-z"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-024-05893-1"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.852583"},{"key":"e_1_3_7_44_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071641"},{"key":"e_1_3_7_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00760-8"},{"key":"e_1_3_7_46_2","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2020.1069"},{"key":"e_1_3_7_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2020.03.009"},{"key":"e_1_3_7_48_2","first-page":"3674","article-title":"Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study","volume":"16","author":"Tanioka H","year":"2018","unstructured":"Tanioka H, Asano M, Yoshida R, et al: Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study. Oncol Lett 16:3674-3680, 2018","journal-title":"Oncol Lett"},{"key":"e_1_3_7_49_2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11063"},{"key":"e_1_3_7_50_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1701-3"},{"key":"e_1_3_7_51_2","doi-asserted-by":"publisher","DOI":"10.5301\/tj.5000356"},{"key":"e_1_3_7_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.9170"},{"key":"e_1_3_7_53_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2009.0056"},{"key":"e_1_3_7_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.003"},{"key":"e_1_3_7_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goaa026"},{"key":"e_1_3_7_56_2","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2014.895036"},{"key":"e_1_3_7_57_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0558"},{"key":"e_1_3_7_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102488"},{"key":"e_1_3_7_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214963"},{"key":"e_1_3_7_60_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7855"},{"key":"e_1_3_7_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61900-X"},{"key":"e_1_3_7_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033025"},{"key":"e_1_3_7_63_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt523"},{"key":"e_1_3_7_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv197"},{"key":"e_1_3_7_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50026-4"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-00646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:59:45Z","timestamp":1792015185000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-00646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1200\/OP-25-00646"],"URL":"https:\/\/doi.org\/10.1200\/op-25-00646","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2025-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}